Incyte (INCY) reported $5.1B in revenue for fiscal 2025, +21.2% year on year. That ranks #796 by revenue among 2853 SEC filers and #70 in Healthcare. Net income was $1.3B, a net margin of 25.0%. Revenue has grown 33.0% a year on average since 2011 ($94.5M then). The fiscal 2025 balance sheet shows $7.0B in total assets, $3.1B in cash and $19.1M in long-term debt.
Scale corrected: the company's XBRL data reports long-term debt (÷10³) without the scale factor (for example "4,801" for 4.8 billion). The figures are shown at the corrected scale; each links to the filing it comes from.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $5.1B | +21.2% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $1.5B | +2,368.6% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $1.3B | +3,846.9% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.4B | +321.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $77.8M | −57.0% | FY20222022-12-31 |
| Total assetsAssets | $7.0B | +27.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $5.2B | +49.9% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $3.1B | +83.5% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $19.1M | −28.8% | FY20182018-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $1.3B | $303M | Open → |
| Q2 20262026-06-30 | $1.7B | $586M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 19 of 161 companies compared | 25.0% | |
| Operating marginRank 16 of 160 companies compared | 29.5% | |
| R&D as share of revenueRank 9 of 102 companies compared | 39.9% | |
| Cash as share of revenueRank 5 of 160 companies compared | 60.3% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Incyte Corp
- Ticker
- INCY
- Exchange
- Nasdaq
- SIC classification
- Services-Commercial Physical & Biological Research (8731)
- Fiscal year end
- 12-31
- CIK
- 0000879169
Filings
- 10-QJul 28, 2026Open filing →
- 10-QApr 28, 2026Open filing →
- 10-KFeb 10, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Beone MedicinesONC | $5.3B | $287M |
| Pacs GroupPACS | $5.3B | $192M |
| ResmedRMD | $5.1B | $1.4B |
| IncyteINCY | $5.1B | $1.3B |
| Bausch & LombBLCO | $5.1B | −$360M |
| Ensign GroupENSG | $5.1B | $344M |
| HerbalifeHLF | $5.0B | $228M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Incyte — Key figures |url=https://companiesranked.com/en/company/incyte |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Incyte — Key figures. CompaniesRanked. https://companiesranked.com/en/company/incyteBibTeX
@misc{companiesranked-en-company-incyte-2026,
author = {{CompaniesRanked}},
title = {{Incyte — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/incyte}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000879169-26-000010 · February 10, 2026
{{cite web |title=Incyte — Key figures — 10-K (0000879169-26-000010) |url=https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-10}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.